Last reviewed · How we verify
Ticagrelor pediatric tablets
At a glance
| Generic name | Ticagrelor pediatric tablets |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT) (PHASE3)
- A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor pediatric tablets CI brief — competitive landscape report
- Ticagrelor pediatric tablets updates RSS · CI watch RSS
- AstraZeneca portfolio CI